GO
Loading...

Eli Lilly and Co

More

  • WASHINGTON, June 27- The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann. It acts more rapidly than traditional injected insulin sold by Eli Lilly and Co and Denmark's Novo Nordisk.

  • A three-judge panel of the 6th U.S. Circuit Court of Appeals in Cincinnati rejected claims in 67 of the cases. Among the defendants in the various cases were Eli Lilly& Co, which won regulatory approval for Darvon in 1957 and Darvocet in 1972, and generic drug makers such as Mylan Inc and Teva Pharmaceutical Industries Ltd..

  • *Sanofi hit may be limited as EU market smaller than U.S. LONDON, June 27- European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015..

  • *Novo Nordisk deputy CEO sees group growing 10 pct annually. COPENHAGEN, June 25- Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • Medtronic’s $43B Covidien deal: More to come? Monday, 16 Jun 2014 | 9:26 AM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.

  • Diabetes: The $54 billion battleground Friday, 13 Jun 2014 | 12:17 PM ET
    Daily implements of diabetes care.

    Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • Midday movers: General Electric, Eli Lilly & More Wednesday, 11 Jun 2014 | 1:02 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Wednesday's midday movers:

  • UPDATE 1-Lilly's Cyramza fails in liver cancer trial Wednesday, 11 Jun 2014 | 10:13 AM ET

    June 11- Eli Lilly and Co's recently approved stomach cancer drug Cyramza failed to prolong the lives of patients with advanced liver cancer in a late-stage trial, the drugmaker said on Wednesday.

  • CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.

  • BRUSSELS/ OTTAWA, June 2- Canada and the European Union are struggling to finalize a multibillion-dollar trade pact six months after political leaders said it was sealed, an embarrassment for Brussels as it seeks a far bigger deal with the United States.

  • ZURICH, June 2- Roche is betting the same tools that made it the world's largest producer of cancer drugs will help it tackle the growing public health crisis of antibiotic resistance as regulators and politicians encourage fresh research.

  • BRUSSELS/ OTTAWA, June 2- Canada and the European Union are struggling to finalize a multi-billion dollar trade pact six months after political leaders said it was sealed, an embarrassment for Brussels as it seeks a far bigger deal with the United States.

  • Early movers: BRCM, MYL, GOOG, Z & more Monday, 2 Jun 2014 | 7:37 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • May 31- Eli Lilly and Co's cancer drug ramucirumab modestly extended survival in a large, late-stage study of patients with advanced, nonsmall cell lung cancer who had relapsed following initial treatment, according to data presented on Saturday.

  • Erectile drug moves closer to over the counter Thursday, 29 May 2014 | 8:50 AM ET

    Men with ED may be able to avoid the awkwardness of a doctor's visit by buying Cialis without a prescription, under a new proposal. NYT reports.

  • COPENHAGEN, May 28- Danish drugmaker Novo Nordisk, the world's biggest insulin producer, said on Wednesday it had decided to launch its diabetes drug Tresiba in Germany on May 1 after seeing signs of a more favourable pricing situation there.

  • Early movers: AGN, VRS, GE, GOOG & more Wednesday, 28 May 2014 | 7:37 AM ET

    Some of the names on the move ahead of the open.

  • Sanofi, Lilly pursue Cialis over-the-counter approval Wednesday, 28 May 2014 | 2:10 AM ET

    PARIS, May 28- Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and U.S. drugmakers said in a statement on Wednesday.